Document is current
Any future updates will be listed below
-
Authors
Meyer, Michelle https://orcid.org/0000-0002-9704-205X
Gunn, Bronwyn M. https://orcid.org/0000-0001-8904-9334
Pietzsch, Colette https://orcid.org/0000-0002-0759-3983
Subramani, Chandru
Kedarinath, Kritika
Villarreal, Paula P. https://orcid.org/0000-0002-8320-7271
Hyde, Matthew A.
Saphire, Erica Ollmann https://orcid.org/0000-0002-1206-7451
Crowe, James E. Jr. https://orcid.org/0000-0002-0049-1079
Alter, Galit https://orcid.org/0000-0002-7680-9215
Himansu, Sunny https://orcid.org/0000-0002-7954-9674
Carfi, Andrea https://orcid.org/0000-0001-5508-3809
Bukreyev, Alexander https://orcid.org/0000-0002-0342-4824
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1 R01 AI41661-01)
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 13 May 2025
First Online: 1 July 2025
Competing interests
: S.H. and A.C. are employees of Moderna. J.E.C. Jr. has served as a consultant for Luna Labs USA, Merck Sharp & Dohme Corporation, Emergent Biosolutions, and BTG International Inc. and is a member of the scientific advisory board of Meissa Vaccines, a former member of the scientific advisory board of GigaGen (Grifols), and is a founder of IDBiologics. J.E.C, Jr’s laboratory received unrelated sponsored research agreements from AstraZeneca, Takeda Vaccines, and IDBiologics. A.B. is a co-founder and vice-president of Emervax, Inc. The remaining authors declare no competing interests.
